1.55
-0.05(-3.13%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.63 |
| Day High | 1.69 |
| Day Low | 1.46 |
| 52-Week High | 9 |
| 52-Week Low | 1.17 |
| Volume | 58,900 |
| Average Volume | 285,798 |
| Market Cap | 7.18M |
| PE | -0.29 |
| EPS | -5.26 |
| Moving Average 50 Days | 2.01 |
| Moving Average 200 Days | 2.4 |
| Change | -0.05 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $155 as of February 21, 2026 at a share price of $1.55. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $828.88 as of February 21, 2026 at a share price of $1.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
Photo Kate Rochlin, Ph.D., President & COO NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO an
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) S